| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
CGI1746 (CGI-1746) is a reversible/non-covalent and highly selective small-molecule inhibitor of the Bruton's tyrosine kinase-Btk with potential anti-inflammatory activity. It inhibits BTK with an IC50 of 1.9 nM. CGI-1746 shows high in vivo antiinflammatory efficacy in an anti-collagen II antibody–induced arthritis (CAIA) model in mice.
| ln Vitro |
CGI1746 is selective for Btk, with approximately 1,000-fold selectivity over Tec and Src family kinases. In an ATP-free competition binding test, Btk's dissociation constant is 1.5 nM. CGI1746 suppresses Btk activity by a novel binding mechanism that stabilizes an inactive, nonphosphorylated enzyme structure. CGI1746 inhibits both the auto- and transphosphorylation processes required for enzyme activation. CGI1746 completely reduces anti-IgM-induced murine and human B cell proliferation at IC50s of 134 nM and 42 nM, respectively, but has no effect on anti-CD3- or anti-CD28-induced T cell proliferation. CGI1746 effectively inhibits the proliferation of CD27+IgG+ B cells isolated from the tonsils of four human donors, with an average IC50 of 112 nM. CGI1746 prevents macrophages from producing TNFα, IL-1β, and IL-6 triggered by FcγRIII. CGI1746 suppresses TNFα, IL-1β, and IL-6 production (with three- to eight-fold greater IC50) in human monocytes challenged with immobilized or soluble immune complexes [1]. CGI-1746 does not kill cells as effectively as irreversible BTK inhibitors at the same dose. CGI-1746 inhibits BTK phosphorylation at tyrosine 233 in the SH3 domain, but it does not kill LNCaP or DU145 prostate cancer cells at the same concentrations as Ibrutinib or AVL-292 [2]. However, it significantly reduces phosphorylation of both the BTK-A and BTK-C proteins, indicating that auto-phosphorylation of the BTK-C isoform is inhibited in a manner similar to that of BTK-A.
|
||
|---|---|---|---|
| ln Vivo |
CGI1746 inhibits B cell-dependent arthritis. CGI1746 treatment (100 mg/kg, sc, twice-daily dosing) results in a 97% inhibition of overall clinical arthritis scores. CGI1746 treatment significantly reduces TNFα, IL-1β, and IL-6, as well as MCP1 and MIP-1α, on both the mRNA and protein levels in the passive anti-collagen II antibody-induced arthritis (CAIA) model. CGI1746 effectively reduces clinical scores and joint inflammation in mice and rats with established arthritis, similar to TNFα blockade [1].
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C34H37N5O4
|
|
|---|---|---|
| Molecular Weight |
579.69
|
|
| Exact Mass |
579.284
|
|
| CAS # |
910232-84-7
|
|
| Related CAS # |
|
|
| PubChem CID |
24857323
|
|
| Appearance |
White to light yellow solid powder
|
|
| Density |
1.2±0.1 g/cm3
|
|
| Index of Refraction |
1.627
|
|
| LogP |
3.42
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
7
|
|
| Heavy Atom Count |
43
|
|
| Complexity |
1070
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
JIFCFQDXHMUPGP-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C34H37N5O4/c1-22-27(7-6-8-28(22)37-31(40)23-9-13-25(14-10-23)34(2,3)4)29-21-38(5)33(42)30(36-29)35-26-15-11-24(12-16-26)32(41)39-17-19-43-20-18-39/h6-16,21H,17-20H2,1-5H3,(H,35,36)(H,37,40)
|
|
| Chemical Name |
4-(tert-butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.31 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7251 mL | 8.6253 mL | 17.2506 mL | |
| 5 mM | 0.3450 mL | 1.7251 mL | 3.4501 mL | |
| 10 mM | 0.1725 mL | 0.8625 mL | 1.7251 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
